B E De Pauw
Overview
Explore the profile of B E De Pauw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donnelly J, De Pauw B, Lane-Allman E
Hematology
. 2016 Jul;
5(6):413-20.
PMID: 27419343
To investigate whether or not the considerable regional differences in prescribing further modifications to initial empirical regimen were due to differences in the patient populations or were the result of...
2.
De Pauw B
Leuk Suppl
. 2016 May;
1(Suppl 2):S22-3.
PMID: 27175237
Fungi are typically opportunistic pathogens. Formerly, limitations in diagnostic techniques explain why invasive fungal infections are usually detected in a late stage of their development. Therefore, traditional guidelines dictate antifungal...
3.
Kullberg B, Verweij P, Akova M, Arendrup M, Bille J, Calandra T, et al.
Clin Microbiol Infect
. 2011 Sep;
17 Suppl 5:1-12.
PMID: 21884296
This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European...
4.
5.
De Pauw B, Sable C, Walsh T, Lupinacci R, Bourque M, Wise B, et al.
Transpl Infect Dis
. 2006 Apr;
8(1):31-7.
PMID: 16623818
Background: Sensitivity analyses were incorporated in a Phase III study of caspofungin vs. liposomal amphotericin B as empirical antifungal therapy for febrile neutropenic patients to determine the impact of varying...
6.
7.
Verweij P, De Pauw B, Meis J
IDrugs
. 2005 Aug;
2(9):925-37.
PMID: 16121307
Voriconazole is undergoing phase III trials by Pfizer as a potential treatment for resistant systemic aspergillosis, candidosis and other emerging fungal infections seen in immunocompromised patients [201603,320737]. The compound demonstrated...
8.
Verweij P, Donnelly J, van Die C, Blijlevens N, Kullberg B, De Pauw B
Ned Tijdschr Geneeskd
. 2005 Apr;
149(11):561-7.
PMID: 15799638
Invasive aspergillosis remains an important cause of morbidity and mortality in patients with prolonged and severe immune suppression such as following haematopoietic stem-cell transplantation. Consensus definitions, which allow categorisation of...
9.
Blijlevens N, Donnelly J, De Pauw B
Bone Marrow Transplant
. 2005 Mar;
35(7):707-11.
PMID: 15785771
We determined gut mucosal barrier injury (MBI) among 129 recipients of an allogeneic or autologous haematopoietic stem cell transplant (HSCT) who had been given different myeloablative regimens by measuring integrity...
10.
Oude Lashof A, De Bock R, Herbrecht R, De Pauw B, Krcmery V, Aoun M, et al.
Eur J Cancer
. 2004 Jun;
40(9):1314-9.
PMID: 15177489
Oropharyngeal candidiasis is a frequent infection in cancer patients who receive cytotoxic drugs. In this study, the efficacy, safety and tolerance of fluconazole and itraconazole were compared in non-neutropenic cancer...